J. Weiss

发表

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

R. Berger, M. Dolled-Filhart, T. Seiwert, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effective management of pain in pediatric hematology and oncology.

J. Weiss, A. Chauhan, R. Warrier, 2010, Asian Pacific journal of cancer prevention : APJCP.

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.

T. Seiwert, D. Pfister, J. Gilbert, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

Jonathan C. Cheng, T. Seiwert, R. Mehra, 2018, British Journal of Cancer.

Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort.

S. Ou, K. Steele, M. Rebelatto, 2015 .

MA16.09 Antitumor Activity and Safety of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer

Jeffrey W. Clark, A. Drilon, M. Socinski, 2017 .

NSCLC in the Elderly—The Legacy of Therapeutic Neglect

C. Langer, J. Weiss, 2009, Current treatment options in oncology.

Phase 2 Trial of De-intensified Chemoradiation Therapy for Favorable-Risk Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.

J. Tepper, N. Hayes, W. Funkhouser, 2015, International journal of radiation oncology, biology, physics.

The addition of chemotherapy to adjuvant radiation is associated with inferior survival outcomes in intermediate‐risk HPV‐negative HNSCC

A. Olshan, D. Hayes, M. Gulley, 2021, Cancer medicine.

Comparative Effectiveness and Resource Usage in Patients Receiving First‐line Taxane‐based Chemotherapy for Stage IV Non–Small‐cell Lung Cancer in a US Community Oncology Setting

Manish B. Patel, J. Weiss, Sandra Margunato‐Debay, 2017, Clinical lung cancer.

Using the galactose‐α‐1,3‐galactose enzyme‐linked immunosorbent assay to predict anaphylaxis in response to cetuximab

D. Hayes, J. Gilbert, B. Murphy, 2016, Cancer.

Improved patient and regimen selection in locally advanced rectal cancer: who, how, and what next?

D. Haller, J. Plastaras, D. Moghanaki, 2009, Clinical colorectal cancer.

Adjuvant Therapy for Lung Cancer in the Elderly

C. Langer, J. Weiss, 2011 .

Novel induction therapy transoral surgery treatment paradigm with risk-adapted adjuvant therapy for squamous cell carcinoma of the head and neck - Mature clinical and functional outcomes.

J. Grilley-Olson, A. Deal, M. Weissler, 2020, Oral oncology.

Phase 1 trial of adavosertib (AZD1775) in combination with concurrent radiation and cisplatin for intermediate‐risk and high‐risk head and neck squamous cell carcinoma

G. Gupta, D. Goldin, D. Moore, 2021, Cancer.

Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer

G. Gupta, J. Grilley-Olson, W. Mendenhall, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.

D. Fried, G. Gupta, N. Hayes, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of Life for Patients With Favorable-Risk HPV-Associated Oropharyngeal Cancer After De-intensified Chemoradiotherapy.

J. Grilley-Olson, W. Mendenhall, R. Amdur, 2019, International journal of radiation oncology, biology, physics.

Mature results of a prospective study of deintensified chemoradiotherapy for low‐risk human papillomavirus‐associated oropharyngeal squamous cell carcinoma

D. Hayes, J. Tepper, J. Grilley-Olson, 2018, Cancer.

Phase 2 trial of neoadjuvant chemotherapy and transoral endoscopic surgery with risk‐adapted adjuvant therapy for squamous cell carcinoma of the head and neck

D. Hayes, J. Grilley-Olson, A. Deal, 2018, Cancer.

Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib.

R. Camidge, B. Kavanagh, H. Borghaei, 2019, Cancer treatment and research communications.

Bevacizumab in adjuvant treatment of non-small-cell lung cancer.

J. Weiss, 2017, The Lancet. Oncology.

Adjuvant Cisplatin and Docetaxel for Non-small Cell Lung Cancer: The Hospital of the University of Pennsylvania Experience

J. Shrager, J. Cooper, C. Langer, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration

J. Parker, Jing Chen, Qi-xiang Li, 2022, Nature Communications.

Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer

J. Akulian, I. Davis, C. Pecot, 2022, Journal for ImmunoTherapy of Cancer.

Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer

G. Gupta, J. Grilley-Olson, W. Mendenhall, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer.

M. Dolled-Filhart, K. Emancipator, T. Seiwert, 2014 .

Nab‐paclitaxel in older patients with non–small cell lung cancer who have developed disease progression after platinum‐based doublet chemotherapy

M. Socinski, T. Stinchcombe, Carrie Lee, 2020, Cancer.

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

T. Owonikoko, P. Roberts, J. Hamm, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients.

J. Lunceford, T. Mcclanahan, M. Ayers, 2015 .

Real-World Treatment Patterns and Outcomes Among Patients With Metastatic NSCLC Previously Treated With Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Inhibitors

J. Weiss, A. Kalsekar, K. Amiri, 2022, JTO clinical and research reports.

nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis

M. Socinski, C. Gridelli, Michael Thomas, 2021, Frontiers in Oncology.

nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC

Edward S. Kim, C. Langer, J. Goldman, 2018, Front. Oncol..

PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers

A. Drilon, M. Burkard, Melissa L. Johnson, 2019, Journal of Thoracic Oncology.

A case of metastatic NUT carcinoma with prolonged response on gemcitabine and nab‐paclitaxel

W. Yarbrough, A. Zanation, Colette J. Shen, 2021, Clinical case reports.

Plasma Circulating Tumor HPV DNA for Early Detection of Cancer Recurrence in HPV-associated Oropharyngeal Cancer

G. Gupta, J. Grilley-Olson, W. Mendenhall, 2019, International Journal of Radiation Oncology*Biology*Physics.

Mature follow up of induction chemotherapy with carboplatin, nab-paclitaxel, cetuximab in head and neck squamous cell carcinoma.

D. Hayes, J. Liao, J. Gilbert, 2022, Oral oncology.

Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer

D. Gerber, Carrie Lee, J. Schiller, 2021, Frontiers in Oncology.

Public attitudes about lung cancer: stigma, support, and predictors of support

A. Copeland, L. Edwards, B. Stephenson, 2014, Journal of multidisciplinary healthcare.

Rates of Renal Toxicity in Cancer Patients Receiving Cisplatin With and Without Mannitol

J. Grilley-Olson, C. Walko, A. Snavely, 2014, The Annals of pharmacotherapy.

Phase 2 study of dalantercept in recurrent or metastatic squamous cell carcinoma of the head and neck.

A. Jimeno, A. Argiris, L. Wirth, 2014 .

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.

T. Owonikoko, P. Roberts, J. Hamm, 2019 .

Incidence of cetuximab-related infusion reactions in oncology patients treated at the University of North Carolina Cancer Hospital

C. Walko, B. Stephenson, B. O'Neil, 2014, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors

Craig B. Davis, C. Chung, Melissa L. Johnson, 2019, Journal of Immunotherapy for Cancer.

Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck Cancer.

Aaron D. Falchook, D. Hayes, E. Basch, 2016, JAMA otolaryngology-- head & neck surgery.

Capecitabine and lapatinib for the first‐line treatment of metastatic/recurrent head and neck squamous cell carcinoma

D. Hayes, W. Hwang, C. Langer, 2016, Cancer.

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.

A. Drilon, Y. Ohe, J. Wolf, 2022, The Lancet. Oncology.

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.

A. Drilon, M. Burkard, T. Owonikoko, 2020, The New England journal of medicine.

Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability–high (MSI-H) tumors.

P. Ascierto, J. Nemunaitis, N. Segal, 2019, Journal of Clinical Oncology.

Abstract CT011: Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers

A. Drilon, L. Bazhenova, B. Konda, 2021, Clinical Trials.

Surgery alone for transorally resected human papillomavirus–driven head and neck cancer—can we de‐intensify adjuvant therapy to 0 Gy and 0 mg/m2?

J. Weiss, 2021, Cancer.

Cetuximab + capecitabine + irinotecan (CCI) versus cetuximab + capecitabine + oxaliplatin (CCO) as first line therapy for patients with metastatic colorectal cancer (CRC): Preliminary results of a randomized phase II trial of the AIO CRC Study Group.

M. Stauch, V. Heinemann, D. Oruzio, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication

D. Hayes, B. Vincent, R. Mehra, 2020, Clinical Cancer Research.

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C.

C. Paweletz, J. Christensen, S. Ou, 2022, The New England journal of medicine.

Biomarkers predictive of response to pembrolizumab in head and neck cancer

J. Lunceford, M. Ayers, R. Cristescu, 2022, Cancer medicine.

Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC).

T. Seiwert, D. Pfister, J. Gilbert, 2016 .

Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC).

Jeffrey W. Clark, A. Drilon, M. Socinski, 2016 .

Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays

D. Hayes, J. Parker, E. Papaemmanuil, 2018, Clinical Cancer Research.

Evaluation of a non-isotopic polymerase chain reaction assay for detection in clinical specimens of herpes simplex virus type 2 DNA. Canadian Women's HIV Study Group.

G. Guibinga, F. Coutlée, C. Hankins, 1997, Clinical and diagnostic virology.

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.

J. Lunceford, T. Mcclanahan, R. Berger, 2016, The Lancet. Oncology.

Abstract LB-339: Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC)

R. Cristescu, R. Mogg, A. Webber, 2018, Clinical Research (Excluding Clinical Trials).

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.

A. Drilon, Keunchil Park, Y. Ohe, 2020, The New England journal of medicine.

CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy

T. Owonikoko, P. Roberts, K. Dragnev, 2020, Journal for ImmunoTherapy of Cancer.

Tumor agnostic efficacy of selpercatinib in patients with RET fusion+ solid tumors: A global, multicenter, registrational trial update (LIBRETTO-001).

A. Drilon, Y. Ohe, B. Konda, 2022, Journal of Clinical Oncology.

Trilaciclib (trila) preserves and enhances immune system function in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy.

T. Owonikoko, K. Dragnev, J. Sorrentino, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Landscape and selection of vaccine epitopes in SARS-CoV-2

Oliver C. Grant, Erik P. Garrison, M. Heise, 2021, Genome medicine.

Landscape and Selection of Vaccine Epitopes in SARS-CoV-2

Oliver C. Grant, Erik K. Garrison, M. Heise, 2020, Genome Medicine.

Factor XIIIA—expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking

D. Hayes, M. Wilkerson, V. Godfrey, 2018, Nature Communications.

Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma

J. Lunceford, M. Ayers, R. Cristescu, 2022, Journal for ImmunoTherapy of Cancer.

Advances in the Treatment of Non-Small Cell Lung Cancer: Immunotherapy.

J. Weiss, Shetal A Patel, 2020, Clinics in chest medicine.

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.

D. Schadendorf, N. Aaronson, M. Muller, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Crizotinib in Patients With MET-Amplified NSCLC.

Jeffrey W. Clark, M. Socinski, G. Shapiro, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next-Generation Sequencing and Successfully Treated with a MET Inhibitor.

G. Frampton, Siraj M. Ali, Carrie Lee, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer

David L. Marron, D. Hayes, J. Parker, 2019, Clinical Cancer Research.

Treatment of older patients with head and neck cancer: a review.

B. Chera, J. Weiss, N. VanderWalde, 2013, The oncologist.

Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline.

Nofisat Ismaila, E. Sturgis, S. Yom, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PIK3CA mutation in HPV-associated OPSCC patients receiving deintensified chemoradiation.

J. Parker, G. Gupta, J. Grilley-Olson, 2019, Journal of the National Cancer Institute.

Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer.

J. Weiss, S. Sheth, 2018, Future oncology.

Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).

Patrick Schöffski, Keith Steele, J. Nemunaitis, 2015 .

Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine

M. Socinski, J. Weiss, L. Villaruz, 2023, Frontiers in Oncology.

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012.

R. Berger, T. Seiwert, R. Mehra, 2016 .

Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung Cancer.

M. Socinski, A. Ivanova, Carrie Lee, 2016, Clinical lung cancer.

Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion

T. Owonikoko, J. Weiss, M. Das, 2021, Advances in Therapy.

Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience.

C. Langer, J. Weiss, T. Evans, 2010, Clinical lung cancer.

Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.

C. Paweletz, P. Jänne, E. Vokes, 2019, JAMA oncology.

Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration

Jeffrey W. Clark, A. Drilon, R. Heist, 2019, Nature Medicine.

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

A. Drilon, Keunchil Park, B. Cho, 2021, Clinical Cancer Research.

Clinical Activity, Tolerability, and Long-term Follow-up of Durvalumab in Patients With Advanced NSCLC.

D. Jäger, P. Ascierto, J. Nemunaitis, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.

S. Ou, K. Steele, M. Rebelatto, 2019, European journal of cancer.

Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC).

M. Ayers, R. Cristescu, R. Mogg, 2017 .

Treatment of Lung Cancer in the Elderly Patient

C. Langer, J. Weiss, 2013, Seminars in Respiratory and Critical Care Medicine.

First line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die?

J. Weiss, 2012, Translational lung cancer research.

Treatment of elderly patients with stage IV non-small-cell lung cancer

T. Stinchcombe, J. Weiss, 2012, Expert review of anticancer therapy.

A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy.

M. Socinski, A. Ivanova, J. Grilley-Olson, 2014, Lung cancer.

Classifying squamous cell carcinoma of the head and neck: prognosis, prediction and implications for therapy

D. Hayes, J. Weiss, 2014, Expert review of anticancer therapy.

Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.

Jeffrey W. Clark, S. Ou, S. Ou, 2018 .

Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.

C. Gwaltney, K. Dragnev, K. Skaltsa, 2021, Clinical lung cancer.

A phase 2 study of dalantercept, an activin receptor‐like kinase‐1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

A. Jimeno, A. Argiris, L. Wirth, 2016, Cancer.

Sinonasal Squamous Cell Carcinoma Survival Outcomes Following Induction Chemotherapy vs Standard of Care Therapy

J. Grilley-Olson, A. Zanation, B. Chera, 2022, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

Use of mobile device technology to continuously collect patient-reported symptoms during radiation therapy for head and neck cancer: A prospective feasibility study

Gregg Tracton, Bhishamjit S. Chera, Ethan M. Basch, 2016, Advances in radiation oncology.

A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL.

J. Machiels, M. Ahn, T. Seiwert, 2016 .

Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

J. Lunceford, M. Ayers, R. Berger, 2016 .

Abstract CT217: Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors

K. Harrington, A. Cervantes, E. Calvo, 2021, Clinical Trials.

Image of the month. A hole in the heart.

C. Langer, A. Lin, J. Weiss, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Hole in the Heart

J. Weiss, 2009 .

Stigma, self-blame, and satisfaction with care among patients with lung cancer

A. Copeland, A. Deal, J. Weiss, 2017, Journal of psychosocial oncology.

Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: Interim results from an ongoing phase 1 study.

G. Giaccone, G. Oxnard, A. Krivoshik, 2016 .

A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC).

C. Paweletz, P. Janne, E. Vokes, 2018, Annals of Oncology.

Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC.

G. Giaccone, G. Oxnard, A. Krivoshik, 2015 .

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

T. Seiwert, R. Mehra, L. Chow, 2018, British Journal of Cancer.

Second-Line Therapy for Advanced NSCLC.

T. Stinchcombe, J. Weiss, 2013, The oncologist.

Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.

D. Hayes, J. Liao, J. Gilbert, 2018, Oral Oncology.

OA12.02 Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer

S. C. Wang, A. Drilon, R. Heist, 2018, Journal of Thoracic Oncology.

Chemotherapy for the Lungs

C. Langer, J. Weiss, 2013 .

A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations

G. Giaccone, G. Oxnard, A. Krivoshik, 2017, Clinical Cancer Research.

Induction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell carcinoma of the head and neck

H. Quon, C. Langer, J. Bauman, 2013, Experimental and therapeutic medicine.

Continued Improvement in Quality of Life (QOL) for Patients with Favorable Risk HPV-Associated Oropharyngeal Cancer > 1 Year after Completing De-Intensified Chemoradiotherapy

J. Grilley-Olson, W. Mendenhall, R. Amdur, 2018, International Journal of Radiation Oncology*Biology*Physics.

Decline in circulating viral and human tumor markers after resection of head and neck carcinoma

M. Gulley, L. Thorne, G. Gupta, 2020, Head & neck.

Circulating Tumor HPV16 DNA as a Biomarker of Tumor Genomics and Disease Control in HPV-associated Oropharyngeal Squamous Cell Carcinoma

David L. Marron, D. Hayes, J. Parker, 2018 .

Factor XIIIA—expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking

D. Hayes, M. Wilkerson, V. Godfrey, 2018, Nature Communications.

A phase I trial evaluating NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with advanced cancers.

T. Seiwert, J. Caudell, Colette J. Shen, 2021 .

Clofarabine administered weekly to adult patients with advanced solid tumors in a phase I dose-finding study

N. Senzer, J. Nemunaitis, C. Cunningham, 2004 .

Clofarabine administered weekly to adult patients with advanced solid tumors in a phase I dose-finding study.

N. Senzer, J. Nemunaitis, C. Cunningham, 2004, Journal of Clinical Oncology.

Updated safety and clinical activity of durvalumab monotherapy in previously treated patients with stage IIIB/IV NSCLC.

M. Ahn, N. Segal, A. Gupta, 2017 .

Myelopreservation and reduced use of supportive care with trilaciclib in patients with small cell lung cancer.

K. Dragnev, J. Goldschmidt, S. Morris, 2020 .

Phase Ib Study of Bavituximab With Carboplatin and Pemetrexed in Chemotherapy‐Naive Advanced Nonsquamous Non–Small‐Cell Lung Cancer

M. Socinski, A. Ivanova, J. Grilley-Olson, 2018, Clinical lung cancer.

Safety and antitumor activity of durvalumab monotherapy in patients with pretreated extensive disease small-cell lung cancer (ED-SCLC).

J. Nemunaitis, N. Segal, S. Gadgeel, 2018 .

Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer.

Eric F. Johnson, E. Vokes, S. Feigenberg, 2021, Lung Cancer.

FP14.06 Multicenter Analysis of Mechanisms of Resistance to Osimertinib (O) in EGFR Mutated NSCLC: An ATOMIC Registry Study

J. Nieva, R. Camidge, R. Doebele, 2021, Journal of Thoracic Oncology.

Clinical significance of indeterminate pulmonary nodules in patients with locally advanced head and neck squamous cell carcinoma

D. Fried, N. Hayes, J. Grilley-Olson, 2014, Head & neck.

Preliminary toxicity data from the combination of pembrolizumab and definitive-dose radiotherapy for locally advanced head and neck cancer with contraindication to cisplatin therapy.

T. Seiwert, R. Mehra, J. Grilley-Olson, 2018 .

Phase ib trial of dose-escalating AZD1775 in combination with concurrent radiation and cisplatin for intermediate and high risk head and neck squamous cell carcinoma.

D. Hayes, G. Gupta, J. Grilley-Olson, 2016 .

Personalizing Postoperative Treatment of Head and Neck Cancers.

S. Koyfman, E. Maghami, J. Weiss, 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

LBA31A PHASE IB STUDY OF PEMBROLIZUMAB (PEMBRO; MK-3475) IN PATIENTS (PTS) WITH HUMAN PAPIILLOMA VIRUS (HPV)-POSITIVE AND NEGATIVE HEAD AND NECK CANCER (HNC)

J. Lunceford, R. Berger, M. Dolled-Filhart, 2014 .

Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort

S. Ou, K. Steele, M. Rebelatto, 2016 .

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation

S. Ou, J. Christensen, Melissa L. Johnson, 2020, European Journal of Cancer.

Real-World Treatment Patterns and Outcomes Among Patients With Metastatic NSCLC Previously Treated With Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Inhibitors

J. Weiss, A. Kalsekar, K. Amiri, 2022, JTO clinical and research reports.

A phase 2 study of neoadjuvant chemotherapy plus durvalumab in resectable locally advanced head and neck squamous cell carcinoma.

A. Deal, W. Yarbrough, Steven M. Johnson, 2023, Cancer.

Treatment of elderly patients with stage IV non-small-cell lung cancer

T. Stinchcombe, J. Weiss, 2012, Expert review of anticancer therapy.